Nivolumab, nouvel acteur majeur dans les cancers bronchiques non à petites cellules

Ronan Flippot; Vincent Fallet; Benjamin Besse; Christophe Massard; Marie Wislez; Stéphane Vignot

doi:10.1016/j.bulcan.2015.10.005

Nivolumab, nouvel acteur majeur dans les cancers bronchiques non à petites cellules

Ronan Flippot, Vincent Fallet, Benjamin Besse, Christophe Massard, Marie Wislez, Stéphane Vignot

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

3 Citations (Scopus)

Résumé

Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of two years in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.

Titre traduit de la contribution	Nivolumab, a new hope in non-small cell lung cancer
langue originale	Français
Pages (de - à)	1046-1052
Nombre de pages	7
journal	Bulletin du Cancer
Volume	102
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/j.bulcan.2015.10.005
état	Publié - 1 janv. 2015
Modification externe	Oui

mots-clés

Immunotherapy
Nivolumab
Non-small cell lung cancer

Accès au document

10.1016/j.bulcan.2015.10.005

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{473e40913045413685062296685f8712,

title = "Nivolumab, nouvel acteur majeur dans les cancers bronchiques non {\`a} petites cellules",

abstract = "Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of two years in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.",

keywords = "Immunotherapy, Nivolumab, Non-small cell lung cancer",

author = "Ronan Flippot and Vincent Fallet and Benjamin Besse and Christophe Massard and Marie Wislez and St{\'e}phane Vignot",

note = "Publisher Copyright: {\textcopyright} 2015 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer.",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.bulcan.2015.10.005",

language = "Fran{\c c}ais",

volume = "102",

pages = "1046--1052",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "12",

}

TY - JOUR

T1 - Nivolumab, nouvel acteur majeur dans les cancers bronchiques non à petites cellules

AU - Flippot, Ronan

AU - Fallet, Vincent

AU - Besse, Benjamin

AU - Massard, Christophe

AU - Wislez, Marie

AU - Vignot, Stéphane

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of two years in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.

AB - Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of two years in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.

KW - Immunotherapy

KW - Nivolumab

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84949599437&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2015.10.005

DO - 10.1016/j.bulcan.2015.10.005

M3 - Article 'review'

C2 - 26585939

AN - SCOPUS:84949599437

SN - 0007-4551

VL - 102

SP - 1046

EP - 1052

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 12

ER -